12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Company News  |  Other News

GlaxoSmithKline, J&J, Roche, Sanofi, Innovative Medicines Initiative (IMI) gene/cell therapy, pharmaceuticals, bioinformatics news

The EU's IMI announced details on its fourth wave of research projects with a total budget of over €237 million ($308.8 million) over five years. IMI said it now has 37 ongoing projects with a combined budget of about €800 million ($1 billion).

The new projects include STEMBANCC, which is coordinated by Roche to generate and characterize 1,500 patient-derived human induced pluripotent stem (iPS) cell lines that researchers could use as cell-based toxicity assays and in vivo phenotype drug screening assays. Johnson & Johnson is coordinating the EMIF project to create a common information framework for patient-level data to link and facilitate access to...

Read the full 501 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >